Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk.

Abstract

518 Background: Studies with non-steroidal aromatase inhibitors indicated an increased bone loss risk in postmenopausal early breast cancer (EBC) patients (pts). Exemestane (E, Aromasin), a steroidal aromatase inactivator, might have no bone detrimental effect due to its 17-hydro-metabolite. METHODS We conducted a randomized, double-blind study evaluating… (More)

Topics

  • Presentations referencing similar topics